Eupraxia Pharmac SEC Filings

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding retiring CMO Dr. Mark Kowalski, who will remain as a senior consultant during the transition. Dr. Tambiah brings over 18 years of biopharmaceutical clinical development, medical and regulatory strategy, and commercialization experience, particularly in immunology and late-stage programs.

The company is advancing EP-104GI for Eosinophilic Esophagitis in its RESOLVE Phase 1b/2 trial and previously completed the SPRINGBOARD Phase 2b trial of EP-104IAR for knee osteoarthritis, which met its primary endpoint and most secondary endpoints. Eupraxia’s Diffusphere™ technology is designed for targeted, extended-release, locally delivered therapies in areas of high unmet medical need.

Eupraxia Pharmaceuticals Inc. is highlighting new clinical data for its lead candidate EP-104GI in eosinophilic esophagitis at the Digestive Disease Week 2026 conference. The company will present one oral and three poster abstracts from the ongoing Phase 1b/2 RESOLVE trial, including 36‑week histology, endoscopy and symptom durability results.

Eupraxia will also host a virtual investor event on May 4, 2026, featuring key opinion leaders discussing recurrent esophageal strictures and the potential of EP-104GI, a long-acting submucosal corticosteroid injection. The filing also notes earlier success of EP-104IAR, which met its primary endpoint in a Phase 2b knee osteoarthritis trial.

Eupraxia Pharmaceuticals reported new 36‑week results from the highest dose cohort (Cohort 9, n=3) of its Phase 1b/2a RESOLVE trial testing EP‑104GI in eosinophilic esophagitis. Patients showed robust, sustained improvements in both tissue health and swallowing symptoms compared with their own baselines.

EoEHSS Stage and Grade scores in Cohort 9 improved by 0.59 and 0.53 at week 36, corresponding to 90% and 88% reductions, with benefits seen in both inflammatory and structural components. Peak Eosinophil Count fell 72% from baseline, the largest reduction among all dose levels.

Symptoms, measured by the Straumann Dysphagia Index, improved by an average of 3 points at week 36, meeting the trial’s definition of clinical remission; 2 of 3 patients maintained remission from weeks 8 through 36. Across 31 patients and more than 230 patient‑months of follow‑up, EP‑104GI has been generally well tolerated with no drug‑related serious adverse events, no oropharyngeal candidiasis, and no adrenal or glucose derangements. A placebo‑controlled Phase 2b portion of RESOLVE using high doses is ongoing, with top‑line data expected in Q4 2026.

Eupraxia Pharmaceuticals Inc. filed a Form 6-K highlighting upcoming investor conference participation and summarizing its drug-development focus. The company’s management will hold 1x1 meetings at the Raymond James Biotech Innovation Symposium on April 14, 2026 in New York.

Eupraxia will also present and host 1x1 meetings at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026, with a webcasted presentation on April 21 from 11:00AM to 11:30AM. The company is a clinical-stage biotechnology firm developing locally delivered, extended-release therapies using its proprietary Diffusphere™ micro-sphere technology.

Eupraxia Pharmaceuticals Inc. has scheduled its Annual General Meeting of security holders for June 18, 2026. Holders of common shares on the record date of May 8, 2026 are entitled to receive notice of the meeting and to vote. The meeting is described as an Annual General Meeting, with common shares being the sole class eligible for notice and voting rights. Proxy-related and delivery details for beneficial owners are addressed through TSX Trust Company.

Eupraxia Pharmaceuticals reported encouraging six-month symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. In the top dose group (n=3), patients showed a mean 4-point reduction in Straumann Dysphagia Index scores, where a 3-point drop is considered clinical remission.

Across dose cohorts 4-9, 59% of patients achieved clinical remission at 12 weeks, 76% of evaluable patients maintained remission at 24 weeks, and 67% at 52 weeks. A new 6 mg/site cohort using larger catheters (Cohort 8b) showed substantially better histologic, symptom, and eosinophil reductions than an earlier 6 mg/site cohort, supporting improved drug delivery.

EP-104GI has been well tolerated, with 31 patients and over 220 patient-months of follow-up, no serious adverse events, and no oropharyngeal candidiasis or adrenal or glucose issues reported. The randomized, placebo-controlled Phase 2b portion of RESOLVE, testing 120 mg and 160 mg doses, is ongoing, with top-line data expected in Q3 2026.

Joseph S. Freedman filed Amendment No. 2 to his Schedule 13D on Eupraxia Pharmaceuticals Inc., updating his ownership and recent share purchases. He is deemed to beneficially own 5,843,215 Eupraxia securities, representing 9.0% of the company’s common shares as calculated in the filing.

This total reflects common shares, Series 1 preferred shares, options for 155,000 common shares and 10,000 restricted stock units, as well as holdings by his spouse, a trust for which he is sole trustee, and his minor children, though he disclaims beneficial ownership of the children’s shares. On February 20, 2026, he bought 275,517 common shares and his spouse bought 4,483 shares in an underwritten public offering at $7.00 per share. On February 27, 2026, the trust exercised warrants for 150,000 shares at $2.20 per share, and his children exercised warrants for 20,000 shares at the same price.

Eupraxia Pharmaceuticals Inc. filed its Annual Report on Form 40-F for the fiscal year ended December 31, 2025, providing audited consolidated financial statements, management's discussion and analysis, and corporate governance disclosures.

Shares outstanding were 51,939,206 Common Shares and 8,355,638 Preferred Shares as of December 31, 2025. The filing incorporates the Annual Information Form, the 2025 audited financial statements, the MD&A, auditor consents, and officer certifications as exhibits.

Eupraxia Pharmaceuticals Inc. closed a public equity financing that raised gross proceeds of approximately US$63.2 million. The deal consisted of 7,607,145 common shares at US$7.00 per share and 1,428,571 pre-funded warrants priced at US$6.99999 each.

The company plans to use the funds mainly to advance its EP-104GI program for Eosinophilic Esophagitis, including preclinical work, a Phase 2 trial, preparations for a Phase 3 trial, and related manufacturing and regulatory activities. Additional proceeds will support broader gastrointestinal indications, pipeline research, business development, and general corporate purposes.